Predict your next investment

Cipher Gene company logo
INTERNET | Internet Software & Services / Healthcare
ciphergene.com

See what CB Insights has to offer

Founded Year

2015

Stage

Series B | Alive

About Cipher Gene

Cipher Gene is a precision medicine service vendor dedicated to constructing an automated analysis and interpretation platform of genetic data. Cipher Gene interacts with clinical doctors to understand their needs, and provide data analysis service to help assure doctors' diagnosis quality, and ultimately benefit patients.

Cipher Gene Headquarter Location

B2-A18, VSTARTUP Zhongguancun Street No.15-11, Haidian District

Beijing, Beijing,

China

010-57266055

Latest Cipher Gene News

China Deal Monitor: Everest backs Cipher Gene and more updates

Jul 20, 2020

Premium Genetic data and analysis-focused biotech company Cipher Gene LLC has closed ‘millions of US dollars’ in a pre-B round of funding led by new investor CS Capital. The fresh round was joined by another new backer Shanghai Sova Investment and existing investor Everest Venture Capital. Everest together with Envision (Beijing) Investment and Jiangmen Ventures had invested 10 million yuan ($1.4 million) in Cipher in 2016. The proceeds will be allocated towards new product research, market expansion, business development and beefing up team, it said in a statement. Cipher delivers precision medical solutions mainly for children with genetic diseases. The company uses AI technologies to develop a genetic data interpretation platform to develop approachable therapies. It has forged partnerships with nearly 300 hospitals and clinics. Additionally, Cipher has also raised capital from state-owned Shenzhen Guozhong Venture Capital Management and King Capital in 2018. CHINA DEAL MONITOR DealStreetAsia has also put together a table listing out all prominent venture capital transactions in the Greater China region on July 20, 2020. Continue reading this story with a subscription to DealStreetAsia. Contact us for corporate subscriptions at subs@dealstreetasia.com . Sign up for our newsletter - The Daily Brief Opt out of receiving The Daily Brief in your inbox everyday REGISTER stories_left_placeholderYou have one free story left this month.You have stories_left_placeholder free stories left this month.This is your last free story of the month. Register to continue reading our free content. × We will never share your information with third parties. If you don’t already have an account click the button below to create your account. Join DealstreetAsia's premium subscription service Unlock your competitive advantage in a rapidly evolving landscape. Our packages come with exclusive access to archive content, data, discount on summit tickets & more. Be a part of our growing community now. Singapore Reporter/s In Singapore, we are looking to double our reporting team by this year-end to comprehensively cover the fast-moving world of funded startups and VC, PE & M&A deals. We want reporters who can tell our readers what is really happening in these sectors and why it matters to markets, companies and consumers. The ability to write precisely and urgently is crucial for these roles. Ideal candidates must have to ability to work in a collaborative, dynamic, and fast-changing environment. We want our new hires to be digitally savvy and ready to experiment with new forms of storytelling. Most importantly, we are looking for hard-hitting reporters who work well in a team. Collaboration and collegiality are a must. Following vacancies can be applied for (only in Singapore). Following vacancies can be applied for (only in Singapore). A reporter to track companies/startups that have raised private capital, and have the potential to become unicorns. SEA currently has over 40 companies with a valuation of over $100 million and under $1 billion. A reporter who can get behind the scenes and reveal how funding rounds are put together, or why they’ve failed to materialise. She/he in this role will largely focus on long-format stories. A journalist to track special situations funds, distressed debt and private credit (from the PE angle) across Asia. Singapore Reporter/s In Singapore, we are looking to double our reporting team by this year-end to comprehensively cover the fast-moving world of funded startups and VC, PE & M&A deals. We want reporters who can tell our readers what is really happening in these sectors and why it matters to markets, companies and consumers. The ability to write precisely and urgently is crucial for these roles. Ideal candidates must have to ability to work in a collaborative, dynamic, and fast-changing environment. We want our new hires to be digitally savvy and ready to experiment with new forms of storytelling. Most importantly, we are looking for hard-hitting reporters who work well in a team. Collaboration and collegiality are a must. Following vacancies can be applied for (only in Singapore). Following vacancies can be applied for (only in Singapore). A reporter to track companies/startups that have raised private capital, and have the potential to become unicorns. SEA currently has over 40 companies with a valuation of over $100 million and under $1 billion. A reporter who can get behind the scenes and reveal how funding rounds are put together, or why they’ve failed to materialise. She/he in this role will largely focus on long-format stories. A journalist to track special situations funds, distressed debt and private credit (from the PE angle) across Asia.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Cipher Gene

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Cipher Gene is included in 2 Expert Collections, including Digital Health.

D

Digital Health

11,759 items

O

Omics

1,029 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.